BLUE | bluebird bio, Inc.

Index- P/E- EPS (ttm)-1.71 Insider Own1.20% Shs Outstand102.92M Perf Week0.55%
Market Cap378.76M Forward P/E- EPS next Y-1.68 Insider Trans-1.05% Shs Float81.98M Perf Month-27.44%
Income-123.20M PEG- EPS next Q-0.74 Inst Own81.30% Short Float / Ratio28.65% / 4.88 Perf Quarter-12.47%
Sales4.00M P/S94.69 EPS this Y58.50% Inst Trans14.67% Short Interest23.49M Perf Half Y-54.03%
Book/sh3.45 P/B1.06 EPS next Y14.70% ROA-21.00% Target Price7.00 Perf Year22.48%
Cash/sh3.07 P/C1.19 EPS next 5Y45.80% ROE-55.40% 52W Range2.78 - 8.58 Perf YTD-47.25%
Dividend- P/FCF- EPS past 5Y19.70% ROI-146.30% 52W High-57.46% Beta0.91
Dividend %- Quick Ratio3.00 Sales past 5Y-36.70% Gross Margin-27.50% 52W Low31.29% ATR0.28
Employees323 Current Ratio3.00 Sales Q/Q26.30% Oper. Margin- RSI (14)46.30 Volatility5.21% 7.70%
OptionableYes Debt/Eq0.00 EPS Q/Q112.40% Profit Margin- Rel Volume0.60 Prev Close3.76
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume4.81M Price3.65
Recom2.80 SMA20-2.86% SMA50-0.65% SMA200-36.41% Volume2,875,604 Change-2.93%
Date Action Analyst Rating Change Price Target Change
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Apr-06-22Downgrade Cowen Outperform → Market Perform
Mar-07-22Downgrade Barclays Equal Weight → Underweight $4
Nov-08-21Reiterated Wells Fargo Equal Weight $25 → $16
Nov-08-21Reiterated Wedbush Neutral $22 → $11
Nov-08-21Reiterated RBC Capital Mkts Sector Perform $26 → $14
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
04:05PM Loading…
Apr-27-23 04:05PM
Apr-24-23 03:49PM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
07:00AM Loading…
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
Jan-30-23 09:12AM
Jan-24-23 08:58AM
Jan-22-23 09:00AM
Jan-18-23 08:00PM
Jan-09-23 07:00AM
Jan-07-23 10:07AM
Jan-06-23 07:30AM
Jan-05-23 01:13PM
08:00AM Loading…
Jan-03-23 08:00AM
Dec-28-22 12:32PM
Dec-26-22 08:00AM
Dec-24-22 08:07AM
Dec-21-22 08:54AM
Dec-19-22 01:48PM
Dec-12-22 06:56PM
Dec-10-22 11:30AM
Dec-07-22 11:30AM
Dec-06-22 10:07AM
Nov-30-22 09:48AM
Nov-17-22 10:07AM
Nov-07-22 08:25AM
Nov-02-22 04:05PM
Oct-28-22 10:00AM
Oct-27-22 09:30AM
Oct-04-22 12:00PM
Oct-03-22 03:20PM
Sep-30-22 12:38PM
Sep-24-22 09:45AM
Sep-22-22 05:37AM
Sep-21-22 01:03PM
Sep-20-22 05:00PM
Sep-19-22 01:45PM
Sep-17-22 02:47PM
Sep-16-22 11:51PM
Sep-13-22 06:46AM
Sep-12-22 07:30AM
Sep-10-22 10:15AM
Sep-06-22 10:15AM
Aug-29-22 08:00AM
Aug-23-22 07:20AM
Aug-19-22 06:33PM
Aug-18-22 09:52AM
Aug-17-22 06:37PM
Aug-15-22 08:51AM
Aug-05-22 11:41AM
Aug-04-22 07:25PM
Aug-03-22 10:53AM
Aug-01-22 10:01AM
Jul-14-22 07:54AM
Jul-08-22 10:01AM
Jul-06-22 08:30AM
Jul-05-22 01:29PM
Jul-02-22 05:41AM
Jun-23-22 11:30AM
Jun-18-22 10:15AM
Jun-17-22 12:03PM
Jun-14-22 01:55PM
Jun-13-22 02:25PM
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klima Thomas JSee RemarksJun 02Sale3.504,13014,451133,049Jun 06 04:06 PM
Leschly NickDirectorJan 11Sale7.804,29033,480280,149Jan 13 04:19 PM
Obenshain AndrewPresident and CEOJan 11Sale7.803,17824,802242,690Jan 13 04:19 PM
Colvin Richard AChief Medical OfficerJan 11Sale7.805574,34774,231Jan 13 04:19 PM
Obenshain AndrewPresident and CEONov 04Sale6.411,2638,101245,868Nov 08 05:46 PM
Colvin Richard AChief Medical OfficerNov 04Sale6.412181,39874,788Nov 08 05:46 PM
Leiderman ElisabethDirectorOct 17Sale6.461,0046,49011,466Mar 09 04:06 PM
Cole JasonChief Strategy & Financial OffAug 19Sale5.5314,19478,473189,546Aug 23 04:50 PM
Obenshain AndrewPresident and CEOAug 04Sale4.3921,80595,754247,131Aug 08 04:16 PM
Cole JasonChief Strategy & Financial OffAug 04Sale4.397,44832,707203,740Aug 08 04:16 PM
Eggimann Anne-VirginieChief Regulatory OfficerJul 12Sale4.951,3586,72242,252Jul 14 04:15 PM